{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:14Z","timestamp":1790769314943,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":25,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_8","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:44Z","timestamp":1790764484000},"page":"137-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eplontersen for the Treatment of Hereditary Transthyretin Amyloidosis"],"prefix":"10.1007","author":[{"given":"Abdullah","family":"Zia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"3","key":"8_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75(3):408\u2013427","journal-title":"Brain"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","volume":"14","author":"L Poli","year":"2023","unstructured":"Poli L, Labella B, Cotti Piccinelli S et al. (2023) Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol 14:1242815","journal-title":"Front Neurol"},{"issue":"5","key":"8_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF et al. (2018) Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 57(5):829\u2013837","journal-title":"Muscle Nerve"},{"key":"8_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL et al. (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8: 31","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"8_CR5","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beirao JM et al. (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268(6):2109\u20132122","journal-title":"J Neurol"},{"issue":"1","key":"8_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11897-025-00701-4","volume":"22","author":"YF Ferrari Chen","year":"2025","unstructured":"Ferrari Chen YF, Aimo A, Castiglione V et al. (2025) Etiological treatment of cardiac amyloidosis: standard of care and future directions. Curr Heart Fail Rep 22(1):16","journal-title":"Curr Heart Fail Rep"},{"issue":"1","key":"8_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-023-03886-1","volume":"17","author":"JB Senecal","year":"2023","unstructured":"Senecal JB, Abou-Akl R, Allevato P et al. (2023) Amyloidosis: a case series and review of the literature. J Med Case Rep 17(1):184","journal-title":"J Med Case Rep"},{"issue":"2","key":"8_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","volume":"128","author":"G Palladini","year":"2016","unstructured":"Palladini G, Merlini G (2016) What is new in diagnosis and management of light chain amyloidosis?. Blood 128(2):159\u2013168","journal-title":"Blood"},{"issue":"9","key":"8_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86(9):1036\u20131043","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"8_CR10","doi-asserted-by":"publisher","first-page":"12224","DOI":"10.1016\/S0021-9258(17)39013-0","volume":"260","author":"T Tsuzuki","year":"1985","unstructured":"Tsuzuki T, Mita S, Maeda S et al. (1985) Structure of the human prealbumin gene. J Biol Chem 260(22):12224\u201312227","journal-title":"J Biol Chem"},{"key":"8_CR11","unstructured":"Rowczenio D, Wechalkar A. Mutations in transthyretin gene (TTR): mutations in hereditary amyloidosis. Accessed 2025 November 20. [cited 2025 November 20]. Available from: http:\/\/www.amyloidosismutations.com\/mut-attr.php"},{"issue":"7 Suppl","key":"8_CR12","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA (2017) Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care 23(7 Suppl):S107\u2013S112","journal-title":"Am J Manag Care"},{"issue":"21","key":"8_CR13","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ et al. (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451\u20132466","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"8_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al. (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"13","key":"8_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ (2018) Inotersen: first global approval. Drugs 78(13):1371\u20131376","journal-title":"Drugs"},{"issue":"4","key":"8_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie T (2024) Eplontersen: first approval. Drugs 84(4):473\u2013478","journal-title":"Drugs"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"13","author":"V Mathew","year":"2019","unstructured":"Mathew V, Wang AK (2019) Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Dev Ther 13:1515\u20131525","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"8_CR18","first-page":"10","volume":"25","author":"K Mickle","year":"2019","unstructured":"Mickle K, Lasser KE, Hoch JS et al. (2019) The effectiveness and value of patisiran and inotersen for hereditary transthyretin amyloidosis. J Manag Care Spec Pharm 25(1):10\u201315","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"8_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/ph12020078","volume":"12","author":"L Gales","year":"2019","unstructured":"Gales L (2019) Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals 12(2):78","journal-title":"Pharmaceuticals"},{"issue":"1","key":"8_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ et al. (2021) Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail 8(1):652\u2013661","journal-title":"ESC Heart Fail"},{"issue":"2","key":"8_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/ph12020052","volume":"12","author":"D Al Shaer","year":"2019","unstructured":"Al Shaer D, Al Musaimi O, Albericio F et al. (2019) 2018 FDA tides harvest. Pharmaceuticals 12(2):52","journal-title":"Pharmaceuticals"},{"issue":"15","key":"8_CR22","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques Jr.W, Dasgupta NR et al. (2023) Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330(15):1448\u20131458","journal-title":"JAMA"},{"key":"8_CR23","unstructured":"AstraZeneca. Paying for Wainua (2025). https:\/\/www.wainua.com\/cost-and-affordability. Accessed 2025 November 25"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1182\/blood-2019-129269","volume":"134","author":"RH Falk","year":"2019","unstructured":"Falk RH, Gertz MA, Benson MD et al. (2019) Rationale and design of a phase 3 study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Blood 134:5764","journal-title":"Blood"},{"key":"8_CR25","doi-asserted-by":"crossref","unstructured":"Fontana M, Ambardekar AV, Cappelli F, et al (2026) Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. European Journal of Heart Failure","DOI":"10.1093\/ejhf\/xuag168"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:01:57Z","timestamp":1790766117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_8","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}